GGrantIndex
← Leaderboards

Harry Adolph Drabkin

University Of Colorado Denver

Google Scholar ↗PubMed ↗ORCID ↗
$6,458,393
Attributed
$6,458,393
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $685.8K · FY2005–18
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$6,458,393 · 7
VA$0 · 1

By mechanism

P50$1,872,140 · 2
R01$1,804,080 · 1
P30$1,648,809 · 2
R33$982,030 · 1
R21$151,334 · 1
I01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Base”

Research focus

BaseTherapeutic AgentsGenesDesignTissue BanksCancer Cell LineMolecularTissue BankingReportingTumor Suppressor GenesServicesResource SharingBlood CapillariesResearch PersonnelResponseCell LineCancer CenterDna SequenceConsultMemberDna Sequence AnalysisNeoplasm /Cancer GeneticsCapillaryCytogenetics

Grant awards (35)

The Role of NRP2b in Invasive Lung Cancer Growth and Metastasis$0
I01 · FY2018 · VA · contact PI
The Role of NRP2b in Invasive Lung Cancer Growth and Metastasis$0
I01 · FY2017 · VA · contact PI
DNA SEQUENCING & ANALYSIS CORE$14,340
P30 · FY2016 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$13,755
P30 · FY2015 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$10,963
P30 · FY2014 · CA · contact PI
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery$123,332
P50 · FY2013 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$76,694
P30 · FY2013 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$961
P30 · FY2013 · CA · contact PI
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery$337,498
P50 · FY2012 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$14,371
P30 · FY2012 · CA · contact PI
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery$358,138
P50 · FY2011 · CA · contact PI
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery$380,544
P50 · FY2010 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$89,384
P30 · FY2010 · CA · contact PI
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery$407,604
P50 · FY2009 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$94,558
P30 · FY2009 · CA · contact PI
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery$265,024
P50 · FY2008 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$88,918
P30 · FY2008 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$86,502
P30 · FY2007 · CA · contact PI
Molecular-Genetic Analysis of 3p14 Genomic Stability$318,056
R01 · FY2006 · CA · contact PI
Quantitative HOX Expression as Prognostic Marker in AML$311,740
R33 · FY2006 · CA · contact PI
DNA SEQUENCING & ANALYSIS CORE$47,980
P30 · FY2006 · CA · contact PI
Quantitative HOX Expression as Prognostic Marker in AML$360,097
R33 · FY2005 · CA
Molecular-Genetic Analysis of 3p14 Genomic Stability$325,710
R01 · FY2005 · CA
Molecular-Genetic Analysis of 3p14 Genomic Stability$325,358
R01 · FY2004 · CA
Quantitative HOX Expression as Prognostic Marker in AML$310,193
R33 · FY2004 · CA
Molecular-Genetic Analysis of 3p14 Genomic Stability$322,891
R01 · FY2003 · CA
Alterations of E-cadherin and Proteasome Function in Progression of Lung Cancer$0
P50 · FY2003 · CA
CORE--DNA SEQUENCING AND ANALYSIS$250,404
P30 · FY2002 · CA
CORE--DNA SEQUENCING AND ANALYSIS$250,404
P30 · FY2002 · CA
Quantitative HOX Expression as Prognostic Marker in AML$151,334
R21 · FY2002 · CA
MOLECULAR-GENETIC ANALYSIS OF 3P14 GENOMIC STABILITY$259,145
R01 · FY2001 · CA
CORE--DNA SEQUENCING AND ANALYSIS$250,404
P30 · FY2001 · CA
CORE--DNA SEQUENCING AND ANALYSIS$144,004
P30 · FY2001 · CA
MOLECULAR-GENETIC ANALYSIS OF 3P14 GENOMIC STABILITY$252,920
R01 · FY2000 · CA
CORE--DNA SEQUENCING$215,167
P30 · FY2000 · CA